PubMed:32376394 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":63},"obj":"Sentence"},{"id":"T2","span":{"begin":64,"end":94},"obj":"Sentence"},{"id":"T3","span":{"begin":95,"end":118},"obj":"Sentence"},{"id":"T4","span":{"begin":119,"end":272},"obj":"Sentence"},{"id":"T5","span":{"begin":273,"end":437},"obj":"Sentence"},{"id":"T6","span":{"begin":438,"end":567},"obj":"Sentence"},{"id":"T7","span":{"begin":568,"end":650},"obj":"Sentence"},{"id":"T8","span":{"begin":651,"end":761},"obj":"Sentence"},{"id":"T9","span":{"begin":762,"end":994},"obj":"Sentence"},{"id":"T10","span":{"begin":995,"end":1083},"obj":"Sentence"},{"id":"T11","span":{"begin":1084,"end":1349},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":63},"obj":"Sentence"},{"id":"T2","span":{"begin":64,"end":94},"obj":"Sentence"},{"id":"T3","span":{"begin":95,"end":118},"obj":"Sentence"},{"id":"T4","span":{"begin":119,"end":272},"obj":"Sentence"},{"id":"T5","span":{"begin":273,"end":437},"obj":"Sentence"},{"id":"T6","span":{"begin":438,"end":567},"obj":"Sentence"},{"id":"T7","span":{"begin":568,"end":650},"obj":"Sentence"},{"id":"T8","span":{"begin":651,"end":761},"obj":"Sentence"},{"id":"T9","span":{"begin":762,"end":994},"obj":"Sentence"},{"id":"T10","span":{"begin":995,"end":1083},"obj":"Sentence"},{"id":"T11","span":{"begin":1084,"end":1349},"obj":"Sentence"}],"text":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.\nSevere Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called \"cytokine storm\". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19."}

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":54,"end":62},"obj":"SP_7"},{"id":"T2","span":{"begin":80,"end":85},"obj":"NCBITaxon:10239"},{"id":"T3","span":{"begin":164,"end":175},"obj":"NCBITaxon:11118"},{"id":"T4","span":{"begin":179,"end":189},"obj":"SP_7"},{"id":"T5","span":{"begin":192,"end":203},"obj":"NCBITaxon:11118"},{"id":"T6","span":{"begin":218,"end":226},"obj":"SP_7"},{"id":"T7","span":{"begin":316,"end":322},"obj":"UBERON:0002405;GO:0006955"},{"id":"T8","span":{"begin":322,"end":331},"obj":"GO:0006955"},{"id":"T9","span":{"begin":335,"end":345},"obj":"SP_7"},{"id":"T10","span":{"begin":473,"end":479},"obj":"UBERON:0002405;GO:0006955"},{"id":"T11","span":{"begin":479,"end":488},"obj":"GO:0006955"},{"id":"T12","span":{"begin":558,"end":566},"obj":"SP_7"},{"id":"T13","span":{"begin":610,"end":614},"obj":"UBERON:0010210;GO:0050817"},{"id":"T14","span":{"begin":615,"end":625},"obj":"GO:0050817"},{"id":"T15","span":{"begin":750,"end":760},"obj":"SP_7"},{"id":"T16","span":{"begin":843,"end":861},"obj":"CHEBI:5801;DG_20;CHEBI:5801"},{"id":"T17","span":{"begin":877,"end":881},"obj":"UBERON:0000104"},{"id":"T18","span":{"begin":1049,"end":1065},"obj":"CHEBI:35705;CHEBI:35705"},{"id":"T19","span":{"begin":1066,"end":1071},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T20","span":{"begin":1152,"end":1157},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T21","span":{"begin":1167,"end":1180},"obj":"CHEBI:35718;CHEBI:35718"},{"id":"T22","span":{"begin":1223,"end":1233},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T23","span":{"begin":1235,"end":1250},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T24","span":{"begin":1252,"end":1267},"obj":"GO:0019814"},{"id":"T25","span":{"begin":1269,"end":1277},"obj":"CHEBI:24505;CHEBI:24505"},{"id":"T26","span":{"begin":1302,"end":1308},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T27","span":{"begin":1340,"end":1348},"obj":"SP_7"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.\nSevere Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called \"cytokine storm\". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19."}

{"project":"hydroxychloroquine","denotations":[{"id":"T1","span":{"begin":421,"end":435},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.\nSevere Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called \"cytokine storm\". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19."}